| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2088 | 2010 |
| The tuberous sclerosis complex PB Crino, KL Nathanson, EP Henske New England Journal of Medicine 355 (13), 1345-1356, 2006 | 2087 | 2006 |
| T-cell invigoration to tumour burden ratio associated with anti-PD-1 response AC Huang, MA Postow, RJ Orlowski, R Mick, B Bengsch, S Manne, W Xu, ... Nature 545 (7652), 60-65, 2017 | 1579 | 2017 |
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, ... Cancer cell 18 (6), 683-695, 2010 | 1505 | 2010 |
| Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. H Meijers-Heijboer, A Van den Ouweland, J Klijn, M Wasielewski, ... Nature genetics 31 (1), 2002 | 1421 | 2002 |
| Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance SM Shaffer, MC Dunagin, SR Torborg, EA Torre, B Emert, C Krepler, ... Nature 546 (7658), 431-435, 2017 | 1183 | 2017 |
| Gene-panel sequencing and the prediction of breast-cancer risk DF Easton, PDP Pharoah, AC Antoniou, M Tischkowitz, SV Tavtigian, ... New England Journal of Medicine 372 (23), 2243-2257, 2015 | 1051 | 2015 |
| Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program MS Brose, TR Rebbeck, KA Calzone, JE Stopfer, KL Nathanson, ... Journal of the National Cancer Institute 94 (18), 1365-1372, 2002 | 990 | 2002 |
| Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) N Mavaddat, D Barrowdale, IL Andrulis, SM Domchek, D Eccles, ... Cancer Epidemiology, Biomarkers & Prevention 21 (1), 134-147, 2012 | 805 | 2012 |
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis T Eisen, T Ahmad, KT Flaherty, M Gore, S Kaye, R Marais, I Gibbens, ... British journal of cancer 95 (5), 581-586, 2006 | 803 | 2006 |
| Network modeling links breast cancer susceptibility and centrosome dysfunction MA Pujana, JDJ Han, LM Starita, KN Stevens, M Tewari, JS Ahn, ... Nature genetics 39 (11), 1338-1349, 2007 | 730 | 2007 |
| A population-based study of genes previously implicated in breast cancer C Hu, SN Hart, R Gnanaolivu, H Huang, KY Lee, J Na, C Gao, J Lilyquist, ... New England Journal of Medicine 384 (5), 440-451, 2021 | 698 | 2021 |
| Comprehensive molecular characterization of pheochromocytoma and paraganglioma L Fishbein, I Leshchiner, V Walter, L Danilova, AG Robertson, ... Cancer cell 31 (2), 181-193, 2017 | 691 | 2017 |
| PTEN Mutation Spectrum and Genotype-Phenotype Correlations in Bannayan-Riley-Ruvalcaba Syndrome Suggest a Single Entity With Cowden Syndrome DJ Marsh, JB Kum, KL Lunetta, MJ Bennett, RJ Gorlin, SF Ahmed, ... Human molecular genetics 8 (8), 1461-1472, 1999 | 682 | 1999 |
| Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ... Nature genetics 45 (4), 371-384, 2013 | 662 | 2013 |
| Breast cancer genetics: what we know and what we need KN Nathanson, R Wooster, BL Weber Nature medicine 7 (5), 552-556, 2001 | 655 | 2001 |
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression KHT Paraiso, Y Xiang, VW Rebecca, EV Abel, YA Chen, AC Munko, ... Cancer research 71 (7), 2750-2760, 2011 | 652 | 2011 |
| Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature KS Hoek, NC Schlegel, P Brafford, A Sucker, S Ugurel, R Kumar, ... Pigment cell research 19 (4), 290-302, 2006 | 627 | 2006 |
| A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma AC Huang, RJ Orlowski, X Xu, R Mick, SM George, PK Yan, S Manne, ... Nature medicine 25 (3), 454-461, 2019 | 609 | 2019 |
| HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma JD Gordan, P Lal, VR Dondeti, R Letrero, KN Parekh, CE Oquendo, ... Cancer cell 14 (6), 435-446, 2008 | 600 | 2008 |
